A new deep brain stimulation approach targeting a specific brain region called the cuneiform nucleus has shown the ability to improve walking in Parkinson's disease patients who struggle with gait despite medication. In a pilot study at the University of Miami Miller School of Medicine, all four participants with Parkinson's disease showed significant improvements in stride length, walking speed, and the ability to walk without freezing after receiving this targeted treatment. Why Is Walking Such a Challenge for Parkinson's Patients? Parkinson's disease affects the brain's ability to produce dopamine, a chemical messenger that controls movement and coordination. When dopamine-producing neurons degenerate in a brain region called the substantia nigra, patients experience tremors, muscle stiffness, and slowed movement. But one of the most frustrating symptoms for many patients is difficulty walking, particularly "freezing of gait," where patients feel their feet are suddenly stuck to the ground, often when turning or walking through doorways. Standard deep brain stimulation (DBS) treatments have successfully reduced tremors and rigidity in Parkinson's patients for nearly three decades. However, these conventional approaches haven't effectively addressed walking problems. "We've been doing pretty good for many years in improving the tremors for Parkinson's. But what we've lacked is a way to improve walking for these people," explained Corneliu Luca, M.D., Ph.D., a professor in the Movement Disorders Division at the University of Miami. How Does This New Brain Stimulation Target Work Differently? Researchers identified a specific cluster of cells in the brainstem called the cuneiform nucleus, located within a region known as the mesencephalic locomotor region (MLR). This area acts as the brain's "walking control center," integrating signals like the intention to walk from higher brain areas and routing instructions to the spinal cord. Brian Noga, Ph.D., a research professor of neurological surgery at the University of Miami, discovered through years of laboratory research that stimulating this cluster of cells could produce walking "within seconds, if not instantaneously". Unlike conventional DBS, which targets other brain regions to manage tremor and rigidity, this novel approach directly activates the neural pathways responsible for initiating and controlling walking. "The idea is that we could improve gait by artificially enhancing the signal along these uninjured pathways," Dr. Noga explained. What Did the Pilot Study Show? In the pilot trial, neurosurgeon Jonathan Jagid, M.D., and his surgical team implanted directional electrodes in four Parkinson's patients whose tremor and rigidity responded well to medication but whose walking difficulties did not. After the electrodes were placed, Dr. Luca adjusted each patient's stimulation settings during programming sessions over a six-month period. The results were encouraging. By the end of the study, all four participants demonstrated significant improvements in their walking ability. They showed longer strides, faster turns, and the ability to walk without freezing episodes. "We were able to show that by utilizing standard of care for Parkinson's disease, albeit in a different area of the brain, we could produce a consistent, positive effect," said Dr. Jagid. What Are the Next Steps in Research and Development? Building on these promising pilot results, the research team is advancing on multiple fronts. They are now participating in a larger, multisite Parkinson's trial funded by the Michael J. Fox Foundation, which will enroll 18 patients across the University of Miami and two other medical centers. This expanded trial will help confirm whether the benefits seen in the pilot group hold up in a larger population. In parallel, the team has received FDA approval to launch the first clinical trial testing this approach in patients with incomplete spinal cord injuries. Many spinal cord injuries don't completely sever neural pathways between the brain and body, leaving some communication intact. Researchers believe that stimulating the cuneiform nucleus could strengthen these remaining signals and improve walking ability in this population as well. Steps to Understanding Your DBS Options for Parkinson's - Assess Your Symptoms: Identify which Parkinson's symptoms affect you most, such as tremor, rigidity, or walking difficulties. Different DBS targets address different symptoms, so understanding your primary concerns helps guide treatment decisions. - Discuss Medication Response: Talk with your neurologist about how well your current medications work. DBS is typically considered when medications effectively manage some symptoms but not others, particularly walking or freezing of gait. - Explore Decision-Making Tools: Researchers at the University of Colorado Anschutz Medical Campus developed an evidence-based decision aid to help Parkinson's patients weigh the risks and benefits of DBS. This tool includes personalized feedback on which of your specific symptoms are likely to improve with surgery. - Consider Your Support System: Research shows that women with Parkinson's are more likely to live alone and need detailed information about post-operative support and assistance with daily activities. Ensure you have adequate caregiving resources before pursuing surgery. What Should Patients Know About DBS Decision-Making? A recent study from the University of Colorado Anschutz Medical Campus found that patients with Parkinson's often experience high decisional conflict when considering DBS, with uncertainty, limited knowledge, and unclear values as key barriers to making informed choices. To address this, researchers developed a decision aid that includes educational content, values clarification exercises, and visual risk communication tools. A central feature of this decision aid is a personalized symptom report that allows patients to input their specific symptoms and receive individualized feedback on how likely each symptom is to improve with DBS. This matters because expectations strongly influence satisfaction with DBS outcomes. Some patients report negative experiences when their expectations aren't met, even if they experience motor improvement, particularly if they anticipated changes in areas not directly affected by DBS. Testing of the decision aid yielded highly positive results. Among the participants who evaluated it, 94 percent said they would recommend it, 91 percent found the language easy to follow, and 87 percent were satisfied with its overall quality. The tool is now being evaluated in a randomized clinical trial to assess its impact on decisional conflict and patient outcomes after surgery. For Parkinson's patients struggling with walking despite medication, this new DBS approach offers hope. As research continues and larger trials provide more data, this targeted brain stimulation technique could become an important option for improving mobility and quality of life in people for whom conventional treatments have fallen short.
